脂蛋白(a)与心血管疾病风险的研究进展

Research progress of lipoprotein(a)with cardiovascular risk

脂蛋白(a)[Lp(a)]水平的升高与心血管疾病(CVD)的发生存在显著相关性,这一认识已经逐渐得到了人们的重视。然而,降低Lp(a)的有效方法和降低Lp(a)水平是否能够改善CVD风险的证据仍然不足,导致Lp(a)的重要性还未得到充分肯定。最新的临床和遗传学研究进展揭示了Lp(a)在CVD发病机制中的关键作用。因此,新兴的治疗策略,如前蛋白转化酶枯草杆菌蛋白酶-kexin 9型抑制剂或反义寡核苷酸技术,显示出在降低Lp(a)方面具有一定的潜力。该文对Lp(a)与CVD风险的研究进展作一综述。

There is a significant correlation that the elevation of lipoprotein(a)[Lp(a)]levels is associated with the occurrence of cardiovascular disease(CVD),and this recognition has gradually gained attention.However,evidence on effective ways to lower Lp(a)and whether lowering Lp(a)levels improves cardiovascular disease risk remains insufficient,resulting in the importance of Lp(a)not being fully recognized yet.The latest clinical and genetic research progress reveal the key role of Lp(a)in the pathogenesis of CVD.Therefore,emerging therapeutic strategies,such as proprotein convertase bacillus subtilis protease-kexin type 9 inhibitors or antisense oligonucleotide technology,show some potential in lowering Lp(a).This article reviewed the research progress of Lp(a)and cardiovascular risk.